Javascript must be enabled to continue!
Fibroblasts Promote Resistance to KRAS Silencing in Colorectal Cancer Cells
View through CrossRef
Colorectal cancer (CRC) responses to KRAS-targeted inhibition have been limited due to low response rates, the mechanisms of which remain unknown. Herein, we explored the cancer-associated fibroblasts (CAFs) secretome as a mediator of resistance to KRAS silencing. CRC cell lines HCT15, HCT116, and SW480 were cultured either in recommended media or in conditioned media from a normal colon fibroblast cell line (CCD-18Co) activated with rhTGF-β1 to induce a CAF-like phenotype. The expression of membrane stem cell markers was analyzed by flow cytometry. Stem cell potential was evaluated by a sphere formation assay. RNAseq was performed in KRAS-silenced HCT116 colonospheres treated with either control media or conditioned media from CAFs. Our results demonstrated that KRAS-silencing up-regulated CD24 and down-regulated CD49f and CD104 in the three cell lines, leading to a reduction in sphere-forming efficiency. However, CAF-secreted factors restored stem cell marker expression and increased stemness. RNA sequencing showed that CAF-secreted factors up-regulated genes associated with pro-tumorigenic pathways in KRAS-silenced cells, including KRAS, TGFβ, NOTCH, WNT, MYC, cell cycle progression and exit from quiescence, epithelial-mesenchymal transition, and immune regulation. Overall, our results suggest that resistance to KRAS-targeted inhibition might derive not only from cell-intrinsic causes but also from external elements, such as fibroblast-secreted factors.
Title: Fibroblasts Promote Resistance to KRAS Silencing in Colorectal Cancer Cells
Description:
Colorectal cancer (CRC) responses to KRAS-targeted inhibition have been limited due to low response rates, the mechanisms of which remain unknown.
Herein, we explored the cancer-associated fibroblasts (CAFs) secretome as a mediator of resistance to KRAS silencing.
CRC cell lines HCT15, HCT116, and SW480 were cultured either in recommended media or in conditioned media from a normal colon fibroblast cell line (CCD-18Co) activated with rhTGF-β1 to induce a CAF-like phenotype.
The expression of membrane stem cell markers was analyzed by flow cytometry.
Stem cell potential was evaluated by a sphere formation assay.
RNAseq was performed in KRAS-silenced HCT116 colonospheres treated with either control media or conditioned media from CAFs.
Our results demonstrated that KRAS-silencing up-regulated CD24 and down-regulated CD49f and CD104 in the three cell lines, leading to a reduction in sphere-forming efficiency.
However, CAF-secreted factors restored stem cell marker expression and increased stemness.
RNA sequencing showed that CAF-secreted factors up-regulated genes associated with pro-tumorigenic pathways in KRAS-silenced cells, including KRAS, TGFβ, NOTCH, WNT, MYC, cell cycle progression and exit from quiescence, epithelial-mesenchymal transition, and immune regulation.
Overall, our results suggest that resistance to KRAS-targeted inhibition might derive not only from cell-intrinsic causes but also from external elements, such as fibroblast-secreted factors.
Related Results
Kras Plays An Important Role In Generating Differentiated Blood Cells
Kras Plays An Important Role In Generating Differentiated Blood Cells
Abstract
Background
Kras is a small GTPase essential for mouse embryonic development. Although Kras-/- fetal liver cells reconst...
Mutasi Gen KRAS Ekson 2 Kodon 12 dan 13 Pada Pasien Kanker Kolorektal di RSUP Prof. Dr. I.G.N.G. Ngoerah Tahun 2018-2019
Mutasi Gen KRAS Ekson 2 Kodon 12 dan 13 Pada Pasien Kanker Kolorektal di RSUP Prof. Dr. I.G.N.G. Ngoerah Tahun 2018-2019
Background: Colorectal cancer is commonly found to be regulated by the KRAS gene mutation. Studies reporting the occurrence of mutations in the KRAS gene in Indonesia are still lim...
Unveiling the Mechanisms to Bypass KRAS Inhibition:In VitroInsights into the Influence of Fibroblast-Secretome
Unveiling the Mechanisms to Bypass KRAS Inhibition:In VitroInsights into the Influence of Fibroblast-Secretome
AbstractNovel KRAS-targeted therapies unlocked new treatment options for previously untreatable patients. However, in colorectal cancer (CRC), resistance to KRAS-targeted therapy d...
The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study
The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study
Abstract
Background
KRAS is one of the most frequently mutated oncogenes in colorectal cancer (CRC). Recently, a novel therapy t...
Abstract A13: Applied the proteomics characteristics to detect the inherited colorectal adenomas
Abstract A13: Applied the proteomics characteristics to detect the inherited colorectal adenomas
Abstract
Introduction: Current study found that about one-third of the incidence of colorectal cancer have genetic related. Hereditary nonpolyposis colorectal cancer...
Abstract 1649: Chemically induced chaperone-mediated protein degradation (CHAMP) of KRAS(G12C)
Abstract 1649: Chemically induced chaperone-mediated protein degradation (CHAMP) of KRAS(G12C)
Abstract
Covalent KRAS(G12C) inhibitors have recently shown promising efficacy in the clinic. However, the rapid development of drug resistance compromises their lon...
Mutant KRAS-Associated Proteome Is Mainly Controlled by Exogenous Factors
Mutant KRAS-Associated Proteome Is Mainly Controlled by Exogenous Factors
Understanding how mutant KRAS signaling is modulated by exogenous stimuli is of utmost importance to elucidate resistance mechanisms underlying pathway inhibition failure, and to u...
Abstract 1770: A role of nicotinamide phosphoribosyltransferase in growth of KRAS mutant non-small cell lung cancer
Abstract 1770: A role of nicotinamide phosphoribosyltransferase in growth of KRAS mutant non-small cell lung cancer
Abstract
Background:
KRAS mutations are frequently found in non-small cell lung cancer (NSCLC). The KRAS mutations could be predictive of resistance t...

